Copyright
©2012 Baishideng Publishing Group Co.
World J Clin Oncol. Nov 10, 2012; 3(11): 142-149
Published online Nov 10, 2012. doi: 10.5306/wjco.v3.i11.142
Published online Nov 10, 2012. doi: 10.5306/wjco.v3.i11.142
Patient | Age(yr) | KPS(%) | RPA | Sex | MMSE score | Tumor volume (cc) | MGMT promoter | Tumor location | PFS (mo) | OS (mo) |
1 | 69 | 70 | 5 | M | 28 | 111.8 | Methylated | right frontal | 19.5 | 27.0 |
2 | 73 | 70 | 5 | M | 27 | 34.0 | Unmethylated | left temporal | 3.1 | 9.1 |
3 | 50 | 80 | 5 | F | 26 | 12.9 | Methylated | left temporal | 3.2 | > 36.0 |
4 | 67 | 60 | 5 | F | 28 | 68.3 | Methylated | right frontal | 16.1 | 27.4 |
5 | 71 | 90 | 4 | F | 30 | 44.8 | Methylated | right frontal | 20.3 | > 32.0 |
- Citation: Valle RD, Cerio ALD, Inoges S, Tejada S, Pastor F, Villanueva H, Gallego J, Espinos J, Aristu J, Idoate MA, Andreu E, Bendandi M. Dendritic cell vaccination in glioblastoma after fluorescence-guided resection. World J Clin Oncol 2012; 3(11): 142-149
- URL: https://www.wjgnet.com/2218-4333/full/v3/i11/142.htm
- DOI: https://dx.doi.org/10.5306/wjco.v3.i11.142